Stemgent is a biotechnology company, now operating as a brand under REPROCELL Group, specializing in cellular reprogramming products and services for stem cell research. It develops innovative, non-viral RNA-based kits and tools, such as the StemRNA™ series, to generate high-quality induced pluripotent stem cells (iPSCs) from various cell types like fibroblasts and blood-derived endothelial progenitor cells (EPCs).[1][2][4] These products serve pharmaceutical, biotechnology, academic, and government researchers worldwide, solving challenges in creating safe, footprint-free iPSCs for research, disease modeling, and clinical applications by simplifying reprogramming processes with high efficiency, low genomic risk, and rapid kinetics (as few as 12 days).[3][4][5] Growth has been driven by REPROCELL's acquisitions and advancements, including partnerships for genetically engineered iPSC services and expansions into GMP manufacturing for cell therapies.[2][3][5]
Stemgent originated as an independent U.S.-based company in Cambridge, Massachusetts, focused on partnering with leading stem cell scientists to develop reagents for reprogramming research.[1][3] It was acquired by REPROCELL Incorporated—a venture from the University of Tokyo and Kyoto University that pioneered iPS cell commercialization in 2009—alongside other entities like Reinnervate (UK) and BioServe (US), establishing a global network.[2] Key milestones include launching the StemRNA™-SR Reprogramming Kit in 2015 for blood-derived cells, unveiled at the ISSCR meeting, and evolving to the 3rd and 4th Gen kits, with leadership from CEO Joseph Gentile emphasizing clinician-relevant iPSC lines.[1][4][5] This integration bolstered REPROCELL's expertise, making Stemgent central to mRNA reprogramming commercialization since 2010.[2][5]
Stemgent stands out in stem cell research through its proprietary RNA technologies and service integrations:
Stemgent rides the iPSC revolution in regenerative medicine, enabling patient-specific disease models and therapies amid rising demand for clinical-grade cells post-Shinya Yamanaka's 2006 Nobel-winning discovery.[2][5] Timing aligns with GMP needs for cell therapies, as mRNA methods address viral vector risks, supporting trends in personalized medicine and drug screening.[4][5] Market forces like aging populations and biotech investments favor its high-efficiency tools, influencing the ecosystem by powering pharma R&D, academic breakthroughs, and partnerships that accelerate from reprogramming to differentiated models.[1][3] As part of REPROCELL, it expands global iPSC access, reducing barriers for complex donor cells.[2]
Stemgent's trajectory points to dominance in clinical iPSC manufacturing, with StemRNA™ 4th Gen and GMP services positioning it for cell/gene therapy booms. Trends like AI-driven drug discovery and scalable biomanufacturing will amplify its role, potentially through more editing partnerships and therapeutic licenses. Its influence may evolve from research tools to core enabler of approved therapies, simplifying stem cell workflows as biotech scales globally—echoing its founding mission to advance reprogramming for worldwide scientists.[1][5]
Stemgent has raised $32.0M in total across 3 funding rounds.
Stemgent's investors include Morgenthaler Ventures.
Stemgent has raised $32.0M across 3 funding rounds. Most recently, it raised $11.0M Series B in June 2011.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2011 | $11.0M Series B | Morgenthaler Ventures | |
| Feb 1, 2009 | $14.0M Series B | Morgenthaler Ventures | |
| Jul 1, 2008 | $7.0M Series A | Morgenthaler Ventures |
